POLARIS

Polaris: Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-interventional Study

Objective

This non-interventional study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.

Eligibility

  • Diagnosis of adenocarcinoma of the breast with evidence of metastatic disease or advanced disease not amenable to treatment with curative intent.
  • Documented HR+ (ER+ and/or PR+) tumor based on local standards.
  • Documented HER2- tumor based on local standards.​​​​​​​
  • Physician has determined that treatment with palbociclib is indicated.

NCT ID

NCT03280303